Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Summary

Background Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (TDR) are essential for informing first-line antiretroviral (ARV) therapy guidelines and designing diagnostic assays for use in regions where standard genotypic resistance testing is not affordable. We sought to understand the molecular epidemiology of TDR and to identify the HIV-1 drug-resistance mutations responsible for TDR in different regions and virus subtypes. Methods and Findings We reviewed all GenBank submissions of HIV-1 reverse transcriptase sequences with or without protease and identified 287 studies published between March 1, 2000, and December 31, 2013, with more than 25 recently or chronically infected ARV-naïve individuals. These studies comprised 50,870 individuals from 111 countries. Each set of study sequences was analyzed for phylogenetic clustering and the presence of 93 surveillance drug-resistance mutations (SDRMs). The median overall TDR prevalence in sub-Saharan Africa (SSA), south/southeast Asia (SSEA), upper-income Asian countries, Latin America/Caribbean, Europe, and North America was 2.8%, 2.9%, 5.6%, 7.6%, 9.4%, and 11.5%, respectively. In SSA, there was a yearly 1.09-fold (95% CI: 1.05–1.14) increase in odds of TDR since national ARV scale-up attributable to an increase in non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. The odds of NNRTI-associated TDR also increased in Latin America/Caribbean (odds ratio [OR] = 1.16; 95% CI: 1.06–1.25), North America (OR = 1.19; 95% CI: 1.12–1.26), Europe (OR = 1.07; 95% CI: 1.01–1.13), and upper-income Asian countries (OR = 1.33; 95% CI: 1.12–1.55). In SSEA, there was no significant change in the odds of TDR since national ARV scale-up (OR = 0.97; 95% CI: 0.92–1.02). An analysis limited to sequences with mixtures at less than 0.5% of their nucleotide positions—a proxy for recent infection—yielded trends comparable to those obtained using the complete dataset. Four NNRTI SDRMs—K101E, K103N, Y181C, and G190A—accounted for >80% of NNRTI-associated TDR in all regions and subtypes. Sixteen nucleoside reverse transcriptase inhibitor (NRTI) SDRMs accounted for >69% of NRTI-associated TDR in all regions and subtypes. In SSA and SSEA, 89% of NNRTI SDRMs were associated with high-level resistance to nevirapine or efavirenz, whereas only 27% of NRTI SDRMs were associated with high-level resistance to zidovudine, lamivudine, tenofovir, or abacavir. Of 763 viruses with TDR in SSA and SSEA, 725 (95%) were genetically dissimilar; 38 (5%) formed 19 sequence pairs. Inherent limitations of this study are that some cohorts may not represent the broader regional population and that studies were heterogeneous with respect to duration of infection prior to sampling. Conclusions Most TDR strains in SSA and SSEA arose independently, suggesting that ARV regimens with a high genetic barrier to resistance combined with improved patient adherence may mitigate TDR increases by reducing the generation of new ARV-resistant strains. A small number of NNRTI-resistance mutations were responsible for most cases of high-level resistance, suggesting that inexpensive point-mutation assays to detect these mutations may be useful for pre-therapy screening in regions with high levels of TDR. In the context of a public health approach to ARV therapy, a reliable point-of-care genotypic resistance test could identify which patients should receive standard first-line therapy and which should receive a protease-inhibitor-containing regimen.

Key Points

• 1Transmitted drug resistance varies by region, with significant increases noted in sub-Saharan Africa
• 2Key non-nucleoside reverse transcriptase inhibitor mutations account for most transmitted drug resistance
• 3In sub-Saharan Africa, transmitted drug resistance is linked to a rising prevalence of specific mutations
• 4Point-mutation assays could aid in pre-therapy screening for HIV resistance
• 5Antiretroviral regimens with a high genetic barrier are crucial in managing transmitted drug resistance.

Related articles

• Evaluating large language models for clinical note processing: local fine-tuning and internal-external validation using electronic health records from South Asia

  This research paper evaluates the effectiveness of large language models for processing clinical notes from electronic health records in South Asia, focusing on local fine-tuning and validation. It discusses the potential application of LLMs in clinical settings, particularly in resource-limited environments.

• Cardiac Cycle & Physiology: Understanding Cardiac Function

  This document provides a detailed overview of cardiac physiology, including the cardiac cycle, blood flow processes, and the cardiac conduction system. It aims to inform readers about the mechanics of the heart and its role in circulation.

• Cardiac Cycle & Physiology

  This document provides a comprehensive overview of cardiac cycle phases, blood flow through the heart, and the electrophysiology of cardiac conduction. It details the processes of deoxygenation and oxygenation of blood and the physiological aspects of cardiac output and common cardiovascular assessment findings.

• The Dual Pillars of Clinical and Community Care

  This document provides an in-depth examination of nutritional assessment and surveillance in clinical and community settings, offering guidelines on measuring malnutrition indicators and the importance of dietary interventions.

• Cather Simpson Lecture Research Brief Inaugural David Breen

  Cather Simpson Lecture Research Brief Inaugural David Breen Lecture | 14 October 2026 | 12 pm to 1 pm | AM103 The "Nespresso" of Diagnostics: Centrifugal Microfluidics for Point-of-Care Diagnostics; “Can we